Eagle Pharmaceuticals Inc (EGRX) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Eagle Pharmaceuticals inc   (NASDAQ: EGRX)
 

Eagle Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EGRX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) -12.8 % -7.75 % -2.9 % -2.46 %
Q / Q Revenue Growth (Q2 MRQ) -2.5 % 1 % 1.48 % 1.26 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) -5.38 % -4.27 % -2.33 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) -3.55 % -2.07 % -0.88 % -0.63 %
Revenue 5 Year Average Growth 5.99 % 10.99 % 8.94 % 9.55 %


EGRX's Growth Comparisons in II. Quarter 2023




Eagle Pharmaceuticals Inc reported sharp sales fall by -12.8% from the same quarter a year ago, in the second quarter 2023, despite the minor sales decline in the Major Pharmaceutical Preparations industry by -7.75%, and underperformed the -2.9% Revenue decrease in the Healthcare sector. Weak second quarter sales, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Eagle Pharmaceuticals Inc results which underperformed overall market.

Top-line fell by -2.5% from the first quarter. Average annual sales growth for Eagle Pharmaceuticals Inc is 5.99%, while S & P 500's average yearly sales increase is 9.55%, including only Businesses with the second quarter 2023 financial results.


Growth Rates of EGRX's Income in the second quarter 2023


EGRX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) 367.73 % -64.27 % -55.39 % -12.52 %
Sequential Operating Income Change (Q2 MRQ) -12.48 % -60.7 % -57.37 % -4.07 %
Y / Y Operating Income Growth (Q2 TTM) -29 % -15.55 % -23.02 % -6.7 %
Sequential Operating Income Growth (Q2 TTM) 24.62 % -15.67 % -12.58 % -3.41 %
Operating Income 5 Year Avg. Change 1.82 % 15.5 % 4.67 % 8.71 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -81.18 % -96.85 % -12.23 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) -10.19 % -60.18 % -96.5 % -5.88 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) -47.57 % -41.81 % -47.5 % -9.06 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - -22.19 % -21.26 % -3.4 %
Income from Cont. Ops. 5 Year Avg. Change -7.26 % 16.52 % 8.32 % 11.88 %

EGRX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -81.47 % -95.29 % -10.4 %
Q / Q Net Income Growth (Q2 MRQ) -10.19 % -60.44 % -94.87 % -4.29 %
Y / Y Net Income Change (Q2 TTM) -47.57 % -40.02 % -44.15 % -8.96 %
Sequential Net Income Change (Q2 TTM) - -21.96 % -20.11 % -2.9 %
Net Income 5 Year Avg. Growth -7.26 % 21.26 % 10.49 % 3.58 %

EGRX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -91.55 % -96.85 % -12.23 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) -11.36 % -83.32 % -96.5 % -5.88 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) -49.89 % - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - 31714.25 %
EPS from Cont. Ops. 5 Year Avg. Growth -4.31 % 5.03 % 8.32 % 11.88 %



EGRX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -91.68 % -95.29 % -10.4 %
Q / Q EPS Net Growth (Q2 MRQ) -11.36 % -83.43 % -94.87 % -4.29 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 22065.17 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - - 27229.2 %
EPS Net 5 Year Avg. Change -3.55 % 21.26 % 10.49 % 3.58 %



Eagle Pharmaceuticals Inc reported bottom-line of $ 0.39 in the second quarter, compare to $ -0.74 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -91.68%, while Healthcare sector decreased by -95.29%, and overall market declined by -10.4%.

Sequentially company's EPS fell by -11.36% from the first quarter results. . Looking into annual growth, income per share grew by -3.55% on average in last five years, while S & P 500's including only Businesses with the second quarter 2023 reports, average yearly income per share growth is 3.58%.

EGRX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) - -49.61 % -28.05 % -22.48 %
Sequential Free Cash Flow Change (Q2 MRQ) - 19.7 % 80.04 % 98.02 %
Y / Y Free Cash Flow Change (Q2 TTM) - -34.82 % -30.06 % -12.48 %
Sequential Free Cash Flow Change (Q2 TTM) - -13.59 % -7.09 % -8.48 %
Free Cash Flow 5 Year Avg. Change -1.22 % 8.35 % 6.34 % -24.89 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - -
Sequential Net Cash Flow Change (Q2 MRQ) - - - -
Y / Y Net Cash Flow Change (Q2 TTM) - - - -
Sequential Net Cash Flow Change (Q2 TTM) - - 50.3 % -
Net Cash Flow 5 Year Avg. Change - - -32.87 % 34.23 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) - 11.2 % 5.83 % 12.07 %
Sequential Capital Expenditures Change (Q2 MRQ) -89.66 % 0.77 % -0.31 % 4.78 %
Y / Y Capital Expenditures Change (Q2 TTM) -98.58 % 14.19 % 9.4 % -27.68 %
Sequential Capital Expenditures Change (Q2 TTM) 8.82 % 1.18 % 0.95 % -14.07 %
Capital Expenditures 5 Year Avg. Change -49.05 % 13.35 % 9.54 % 8.4 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.